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Abstract
Intracerebral inoculation of 263K Scrapie brain homogenate (PrPsc) with a self-assembling RADA-peptide (RADA)
significantly delayed disease onset and increased hamster survival. Time of survival was dependent on the dose of RADA
and pre-incubation with PrPsc prior to inoculation. RADA treatment resulted in the absence of detectable PrPsc at 40 d
followed by an increased rate of PrPsc accumulation at 75 d up to sacrifice. In all PrPsc inoculated animals, clinical
symptoms were observed ,10 d prior to sacrifice and brains showed spongiform degeneration with Congo red positive
plaques. A time-dependent increase in reactive gliosis was observed in both groups with more GFAP detected in RADA
treated animals at all time points. The PrP protein showed dose-dependent binding to RADA and this binding was
competitively inhibited by Congo Red. We conclude that RADA disrupts the efficacy of prion transmission by altering the
rate of PrPsc accumulation. This is the first demonstration that a self-assembling biomolecular peptide can interact with
PrPsc, disrupt the course of Scrapie disease process, and extend survival.
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Introduction
Transmissible spongiform encephalopathies are incurable, fatal
neurodegenerative diseases characterized by the accumulation of
abnormal prionprotein (PrPsc), neuronal cell death and vacuolation
of brain [1]. The PrPsc protein is extractable from diseased tissue
and is distinguished from endogenous PrPc by partial protease
resistance and detergent insolubility [2]. The transmissible agent is
the PrPsc protein and it serves as a template for the molecular
conversion of endogenous PrPc into the abnormal PrPsc structural
isoform [1]. Host expression of PrPc is necessary for disease
transmission, as ablation of the PrPc gene prevents disease [3] and
over expression of PrPc followed by PrPsc challenge accelerates
disease [4]. The molecular events that mediate neuronal PrPc to
PrPsc conversion, not simply accumulated PrPsc, appears to be the
initiating factor mitigating the neurodegenerative disease process
[5]. Yet the mechanism responsible for the conformational
conversion of PrPc to an infectious prion remains enigmatic.
The use of synthetic peptides designed with intrinsic functional
domains have been engineered to facilitate drug delivery, cell
attachment, and tissue regeneration [6–8]. These biomolecular
scaffolds exploit the properties of natural protein sequences to
mediate targeted cellular events [9]. They offer distinct advantages
over traditional pharmacotherapies because they are composed of
normal biological constituents, devoid of animal contaminants, and
are biodegradable [10]. Moreover, some of these substrates can
mimic the dynamic structural changes observed in protein mis-
folding diseases [11,12]. The use of these peptides to inhibit
endogenous protein mis-folding may prove useful in the elucidation
of molecular conversion events or therapeutic intervention.
In this report we identify a self-assembling synthetic peptide
composed of a 16-mer RADA repeat that significantly extends
hamster survival when pre-incubated with 263K Scrapie prior to
intracerebral inoculation. RADA combined with Scrapie results in
an initial delay in detectable PrPsc followed by increased
accumulation at later time points. There is a concomitant delay
in observable Scrapie symptoms despite elevated PrPsc levels at
75-days when equivalent control animals required sacrifice.
Moreover, RADA treatment shows a similar time-course for the
induction of reactive gliosis and GFAP as PrPsc alone, but with
increased levels at all time points. Furthermore, we show dose-
dependent binding of PrP to RADA and demonstrate competitive
binding inhibition of PrP to RADA with the amyloid-binding dye
Congo red. We postulate that a physiochemical interaction of
PrPsc with RADA impedes the efficacy of prion conversion and
disease progression by disrupting the rate of PrPsc accumulation
through altered clearance and distribution.
Results
Increased survival time in animals inoculated with PrPsc
and RADA-peptide
Hamsters inoculated with PrPsc combined with RADA survived
significantly longer than those that received an equivalent dose of
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4440PrPsc alone. The mean survival time of animals inoculated with
1% PrPsc (10
22 dose) combined with 0.9% RADA was 114 d
(n=24) as compared to 78 d (n=24) for animals that received
equivalent PrPsc alone or 80 d (n=6) for animals inoculated with
PrPsc-agarose plugs (Fig. 1A; P,0.001). A rapid toxicity was
observed with this combined inoculum in ,20% of the hamsters
within 24 h (Table 1). This toxicity did not occur in animals that
received equivalent doses of PrPsc alone, PrPsc combined with
agarose, RADA alone, or normal brain homogenate combined
with RADA. With increased dilution of PrPsc+RADA there was
reduced morbidity in that 24 h period. No animals died
unexpectedly after this initial 24 h period.
As expected, increased dilution of PrPsc resulted in a dose-
dependent increase in survival time (Fig. 1B; squares). Importantly,
increased dilution of PrPsc with 0.9% RADA resulted in a
significant increase in survival time as compared to the equivalent
doses of PrPsc alone (Fig. 1B; circles; Mann-Whitney P,0.01).
The combined inoculum showed dose-dependence, but a plateau
in total survival time (,125 d) was observed at dilutions of PrPsc
below 2610
24, suggesting that maximal survival promoted by
Figure 1. RADA promotes increased survival of hamsters inoculated with 263K Scrapie. Fig. 1A compares hamster survival in days
(mean6SEM) following intracerebral inoculation with 1% Scrapie alone (PrPsc), Scrapie pre-incubated with 0.9% w/v RADA (PrPsc+RADA) or Scrapie
agarose plugs (PrPsc+agarose). Fig. 1B compares hamster survival in days (mean6SEM) with increased dilution of Scrapie brain homogenate alone
(open squares) to equivalent doses of Scrapie pre-incubated with 0.9% RADA (open circles). Fig. 1C depicts a hamster survival curve in days (N=6;
mean6SEM) with increasing dilution of Scrapie inoculant (open circles). Plotted on the curve (open square) is the mean survival in days of hamsters
inoculated with 10
22 Scrapie combined with 0.9% RADA depicting equivalent titer of Scrapie inoculum. Fig. 1D shows a dose-dependent increase in
hamster survival in days (mean6SEM) with increasing concentration of RADA (open circles) inoculated with 1% Scrapie. A synthetic 16-mer RADA-
peptide was hydrated combined with 1% Scrapie and inoculated. Survival in days was plotted (grey triangle) and used to estimate RADA
concentration.
doi:10.1371/journal.pone.0004440.g001
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263K Scrapie (Fig. 1C; open circles; n=6 each data point) the
initial PrPsc inoculum of 10
22 when combined with RADA was
equivalent to a starting inoculum of 10
29 PrPsc alone, a 7-log
reduction in prion titer (Fig. 1C; dashed line). In all groups
inoculated with PrPsc, clinical Scrapie symptoms (startle response
followed by increased righting reflex and ataxia) began 10–15 d
prior to sacrifice (data not shown). No animals injected with
RADA alone or combined with normal brain homogenate
exhibited Scrapie symptoms and those not sacrificed as age-
matched controls survived .200 days.
Increased survival is RADA-peptide dose-dependent
Increased survival time of hamsters inoculated with PrPsc was
RADA dose-dependent. When RADA concentration was varied
0–1% with a constant 10
22 dose of PrPsc there was a dose-
dependent increase in survival time with maximal survival
achieved at the highest concentration of RADA used (Fig. 1D;
circles). The survival curve was sigmoid suggesting that no
additional increase in survival would be achieved with RADA
concentrations above 1% when combined with the 10
22 PrPsc
dose. We synthesized our own 16-mer RADA-peptide to 95%
purity and estimated the concentration of our preparation to be
,0.2% w/v. This material when combined with PrPsc increased
survival to ,87 d from 80 d compared to PrPsc alone (Mann-
Whitney; P=0.02) and RADA concentration calculated from our
survival curve was ,0.14% (Fig. 1D; triangle).
Total PrP, Prion and GFAP proteins are elevated in brain
of animals inoculated with PrPsc -RADA
Western blot showed increased detection of total PrP protein in
brain homogenate of animals that received combined PrPsc with
RADA (Fig. 2, top left panel) at the time of sacrifice. Both PrPsc
alone and PrPsc combined with RADA had increased PrP protein
compared to animals treated with normal brain homogenate
(PrPc). This increase in total PrP is a measure of both PrPc and
accumulated PrPsc. The highest level of PrP was detected in brain
homogenates from animals treated with PrPsc combined with
RADA. Protein load was normalized by BCA and confirmed by
detection of flotillin-1 which remained unchanged (Fig. 2; bottom
left panel). As expected, PrP from hamsters inoculated with control
Table 1. Effect of RADA on Mortality within 24 h.
Inoculum (ic) 0.9% RADA N Loss ,24 h (N)
RADA alone + 12 0
1% PrPc 2 16 0
1% PrPc + 26 0
1% PrPsc 2 74 0
1% PrPsc Agarose 6 0
1% PrPsc + 43 9
0.02% PrPsc + 82
0.0004% PrPsc + 81
Mortality data at ,24 h following single unilateral intracerebral (ic) inoculation
of brain homogenates and RADA. Normal (PrPc) or Scrapie (PrPsc) infected
hamster brain homogenates were inoculated alone (2) or with 0.9% w/v RADA
(+). Low melt Agarose (0.9% w/v) combined with PrPsc served as an additional
control. RADA alone or combined with PrPc brain homogenate resulted in no
lethality. Combined RADA with PrPsc resulted in a rapid mortality within 24 h in
,20% of the animals inoculated. N=number of hamsters inoculated.
doi:10.1371/journal.pone.0004440.t001
Figure 2. Prion and GFAP proteins are increased in brain homogenates from hamsters inoculated with Scrapie+RADA. Total PrP
protein was detected by Western blot in hamster brain homogenates (20 mg/lane) from normal (PrPc; 75 d), Scrapie infected (PrPsc; 75 d), normal
combined with RADA (PrPc+RADA; 115 d), and Scrapie combined with RADA (PrPsc+RADA; 115 d). A prominent PrP band was detected at ,30 kDa
and two lower molecular weight bands at ,22 kDa and 19 kDa (top left panel). Flotillin-1 (Flot-1) was used as a loading control and a doublet was
detected at ,45 kDa (bottom left panel). Digestion of brain homogenates with proteinase-K (+PK) demonstrated the presence of prion protein in the
PrPsc and PrPsc+RADA samples, but not in PrP
c or PrPc+RADA. A detectable MW shift was observed for PrPsc in all three bands with a shift from
30 kDa to 25 kDa occurring for the predominant band (top right panel). A notable increase in PK-resistant prion was detected in the PrPsc+RADA
compared to the PrPsc alone. Detection of GFAP was used to verify the complete PK-digestion of samples (bottom right panel). Three detectable
GFAP bands were resolved (,50, 45 and 40 kDa) in the non-PK treated samples with increased detection of GFAP in PrPsc+RADA brain.
doi:10.1371/journal.pone.0004440.g002
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RADA (PrPc+RADA), were proteinase-K (PK) sensitive (Fig. 2,
top right panel). Brain homogenates from hamsters inoculated
with PrPsc alone (PrPsc) or combined with RADA (PrPsc+RADA)
had detectable PK-resistant prion, with the greatest amount
detected in brain homogenate from animals that received the
combined inoculant (Fig. 2, top right panel). Glial fibrillary acidic
protein (GFAP) was used to validate the fidelity of the PK reaction
and is completely digested by PK in all groups (Fig. 2, bottom right
panel). Interestingly, more detectable GFAP protein was present in
brain homogenate from the animals that received PrPsc+RADA
(Fig. 2, bottom right panel).
Delayed PrPsc accumulation with RADA-peptide
In contrastto animalsthat receivedinoculation ofPrPsc alone, no
PK-resistant prion was detected by Western blot in brain
homogenates at 40 d from animals that received PrPsc+RADA
(Fig. 3A; top panels; left side). At 75 d the animals that received
PrPsc alone had late stage clinical Scrapie symptoms whereas those
that received PrPsc with RADA had no observable symptoms (data
not shown). At the 75 d time point PK-resistant prion was detected
in brain of animals that received PrPsc alone or combined with
RADA (Fig. 3A; top panel; right side). Detection of GFAP protein
by Western blot increased from day 40 to 75 in animals of both
treatment groups (Fig. 3A; middle panels), but was greater in brains
of animals that received PrPsc+RADA at both time points (Fig. 3C;
P,0.001). Protein load was normalized by BCA and confirmed by
the equal and unchanged detection of the contactin-1 protein which
also served to validate PK digestion (Fig. 3A; bottom panels).
Quantification of Western blots shows at 40 d there is significantly
more PK-resistant prion protein in animals inoculated with PrPsc
alone (Fig. 3B; P,0.001), whereasat 75 d there is significantly more
prion protein in brain homogenate from animals inoculated with
PrPsc+RADA (Fig. 3B; P,0.001).
RADA induced ventricular enlargement and delayed
spongiform degeneration
At the time of sacrifice the brains of hamsters inoculated with
PrPsc+RADA were filled with an increased amount of cerebral
spinal fluid (CSF) compared to animals inoculated with PrPsc
alone, however gross wet weight (,1 g) did not differ significantly
between these treatment groups (data not shown). Coronal brain
sections showed enlarged lateral ventricles from animals that
received PrPsc+RADA at 75 d and 115 d relative to those
inoculated with PrPsc alone or PrPc+RADA (Fig. 4A; top panels).
Typical spongiform degeneration was observed in cortical brain
sections at 75 d from animals inoculated with Scrapie alone and to
a lesser extent those inoculated with RADA (Fig. 4B; bottom
panels). However, at 115 d the brain of PrPsc+RADA inoculated
hamsters had abundant spongiform degeneration equivalent to
levels observed at 75 d in animals inoculated with Scrapie alone.
Importantly, no abnormal ventricular enlargement or spongiform
degeneration was observed in brain sections from animals
inoculated with PrPc+RADA. Hence, ventricular enlargement is
a consequence of the combined action of PrPsc+RADA and not
RADA alone. Moreover, our histopathology indicates that RADA
delayed the progression of cortical spongiform degeneration
induced by PrPsc.
Increased reactive gliosis and PrP protein aggregates in
brain following PrPsc inoculation with RADA-peptide
Hamster brain sections from animals at the time of sacrifice
showed increased immunoreactive GFAP-positive astrocytes
following inoculation with PrPsc alone (day 75) or PrPsc+RADA
(day 115) as compared to animals inoculated with PrPc+RADA
(Fig. 5A; top panels). Few GFAP immunoreactive astrocytes were
detectable at 115 d in control brain (PrPc+RADA) and PrP was
undetectable by immunofluorescence. Animals that received PrPsc
alone showed increased GFAP positive astrocytes with some
detectable PrP protein; whereas those that received PrPsc+RADA
showed a massive increase in immunoreactive GFAP and large
PrP deposits. These immunoreactive PrP-positive aggregates were
PK resistant (data not shown). In addition, PrPsc increased
detection of the microglia/macrophage-specific calcium-binding
protein IBA1 (ionized calcium binding adaptor molecule 1).
Abundant immunoreactive IBA1-positive microglia were detected
in 75 d PrPsc and 115 d PrPsc+RADA brain sections as compared
to minimal detection in sections from animals inoculated with
PrPc+RADA (Fig. 5B; bottom panels). The absence of IBA-1 and
GFAP co-localization demonstrates that the reactive gliosis
induced by PrPsc and PrPsc+RADA involves two distinct glial
cell populations.
PrP binds RADA-peptide and binding is inhibited by
Congo Red
Normal and Scrapie-infected brain homogenates were incubat-
ed with RADA bound to 96-well plates. PrP binding was
dependent on the concentration of RADA with no significant
difference observed between normal or Scrapie brain (Fig. 6A).
Pre-incubation with Congo red resulted in a dose-dependent
inhibition of binding of PrP to RADA with a significant inhibition
of PrP binding observed at 1 mM Congo red (Fig. 6B; Mann-
Whitney; P,0.001). Importantly, the inhibition of PrP binding to
RADA by Congo red was dependent on the order of reagent
addition; inhibition required Congo red pre-incubation with PrP
prior to RADA exposure (Fig. 6C). RADA pre-incubated with
Congo red before or after plate binding was ineffective in
inhibiting the binding of PrP, suggesting that the Congo red
interacts with PrP, not RADA, to inhibit binding.
PrPsc infectivity is not modified by RADA-peptide
We used four independent preparations of RADA combined
with PrPsc to show increased survival time in hamsters was not
limited to a single sample. All treatment groups showed a
significant increase in animal survival compared to those
inoculated with equivalent dose of PrPsc alone (Table 2).
Moreover, when brain homogenate was prepared from animals
inoculated with PrPsc combined with RADA and re-inoculated
back into a new group of hamsters (PrPsc/RADA; dose 10
22)n o
increase in survival was observed (Table 3). This demonstrates that
the property of Scrapie infectivity was not modified by exposure to
the RADA in subsequent passage. The same inoculant when
combined with RADA again (PrPsc/RADA+RADA), resulted in
an increased survival time.
Discussion
The complex molecular events that underlie most neurodegen-
erative diseases are poorly understood. In prion diseases the
mechanism by which PrPc is converted to PrPsc is central to
disease transmission and pathophysiology [1,13]. Indeed, deposi-
tion of PrPsc in the absence of endogenous PrPc is insufficient to
cause disease. Consequently, the disruption of PrPc to PrPsc
conversion and concomitant cellular events provides a useful basis
for therapeutic intervention.
The structural change from primarily alpha-helical PrPc to
beta-sheet PrPsc is thought to underpin the aggregation status,
RADA Peptide Extends Survival
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PrPsc template is necessary to promote conversion of PrPc in
transmitted disease, but mutations in the PrP gene can impart
intrinsic changes in PrPc primary structure that fosters spontane-
ous conformational conversion that leads to abnormal protein
aggregation and prion diseases [1,16]. The existence of multiple
prion strains with differing biochemical and pathophysiological
signatures suggests that a range of stabilized structural isoforms of
PrPsc can be transmitted to PrPc [17,18]. This functional diversity
likely reflects the unique properties of stabilized prion structures
and their ability to complex with distinct compliments of
endogenous factors. Moreover, the neuropathological variability
observed among prion strains may result from a selective targeting
of a strain-specific PrPsc complex to unique cellular or
extracellular sites within the brain [17,19,20]. Hence, disruption
of the prion structure or its interaction with these endogenous
factors would impede PrPc conversion, cellular distribution and
neuropathology.
The disparity observed in the bioactivity of anti-prion agents
such as polyene antibiotics and tricyclic compounds among prion
strains may reflect their differing ability to disrupt PrPsc
interaction with strain specific proteins [21]. These agents likely
interrupt innate PrPsc+ protein interaction thereby modifying
PrPsc distribution and associated cellular conversion events. These
changes might reduce the rate or site of PrPsc accumulation
thereby decreasing efficacy of prion transmission [20,22].
However, impermanent changes to PrPsc structure would
inexorably lead to its replication from PrPc and eventual disease.
This may explain the ability of anti-prion agents to reduce the rate
of PrPsc accumulation and extend animal survival, but not cure
disease. Synthetic peptides derived from the primary sequence of
PrPc have been shown to have anti-prion activity [23]. Peptides
generated against PrPc residues 106–126 or 109–141 prevented
PrPsc conversion in cell-free systems [24,25]. Additionally, the use
of PrP119–136 peptide was effective in decreasing PrPsc in
chronically infected cells [26]. Soto et al generated a peptide
corresponding to the amino acid residues of PrPc with the
propensity to form beta-sheet structure and inserted incremental
proline residues to disrupt the conformational requirements of an
ordered beta-sheet. Pre-incubation of this peptide (iPrP13) with
mouse-adapted Scrapie prior to intracerebral inoculation in-
creased survival time in mice. Moreover, iPrP13 was able to
reduce PrPsc in cultured cells following exposure to Scrapie
infected brain homogenate [23]. This data demonstrates that a
competitive peptide mimetic can impede PrPc to PrPsc conver-
sion, result in reduced PrPsc accumulation and delay disease
progression. Alternatively, transgenic mice expressing mutant
PrP(P101L) at low level persist as clinically normal but can be
induced to develop neurodegeneration and amyloid deposits by
inoculation of a synthetic beta-sheet peptide (PrP89–143) carrying
Figure 3. Time-dependent increase in GFAP and PrP protein in hamsters inoculated with combined Scrapie+RADA. Fig. 3A shows a
Western blot from hamster brain homogenates inoculated with 1% Scrapie alone (Sc) or combined with 0.9% RADA (Sc+RADA) at 40 d and 75 d
treated with (+) or without (2) proteinase-K (PK). The top panels show PrPc and PrPsc detection at each time point (20 mg). Middle panels show
detection of GFAP protein and bottom panel contactin-1. Fig. 3B shows quantification of total PrP (2PK) and prion (+PK) from Western blots at each
time-point. Fig. 3C show quantification of ,55 kDa GFAP band (2PK) from Western blots from each time-point.
doi:10.1371/journal.pone.0004440.g003
Figure 4. Combined inoculation of Scrapie+RADA results in ventricular enlargement and delayed spongiform degeneration. Brain
sections were obtained from hamsters inoculated with 1% Scrapie brain homogenate alone (PrPsc) after 75 d, Scrapie combined with 0.9% RADA
(PrPsc+RADA) after 75 d and 115 d and normal brain combined with RADA (PrPc+RADA) after 115 d. Fig. 4A shows gross morphology from coronal
sections of whole hamster brains. No ventricular enlargement (black arrows) was observed in animals that received inoculation of PrPsc alone (top left
panel) or PrPc+RADA (top right panel), whereas brains from hamsters inoculated with PrPsc+RADA had massive enlargement of lateral ventricles at
both 75 d and 115 d (top middle panels). V=ventricle. Bar=2 mm. Fig. 4B are micrographs from brain sections stained with Hematoxylin showing
spongiform degeneration present in hamsters cortex following inoculation with PrPsc alone after 75 d (bottom left panel; arrows) and PrPsc+RADA
after 75 d and 115 d (middle panels; arrows). No spongiform degeneration was detected in animals inoculated with PrPc+RADA after 115 d (bottom
right panel). Bar=50 mm.
doi:10.1371/journal.pone.0004440.g004
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mimetic can also induce PrPc conversion to PrPsc and promote
disease.
Here we report the anti-prion activity of a synthetic RADA-
peptide repeat that is unrelated to PrPc primary structure and self-
assembles into a hydrated beta-sheet nanofiber matrix [11]. The
RADA hydrogel provides a suitable substrate for neuron
attachment, outgrowth, and regeneration [8,28]. RADA likely
mimics the adhesive proteins present in the extracellular matrix
(ECM) that contain the RGD tri-peptide motif and modulate cell
recognition, adhesion and migration [29]. Indeed, the core RAD
motif in the RADA-peptide is similar to the ubiquitous integrin
receptor binding site RGD [30,31]. The PrP protein has been
shown to interact with the ECM protein laminin, which contains a
RGD domain and has self-assembling properties [32,33].
Additionally, PrP interacts with the 37 kDa/67 kDa laminin
receptor which plays a role in the propagation of Scrapie in vitro
[34]. The increase in survival of rodents treated with sulfated
glycans after Scrapie infection is likely mediated by disruption of
prion/laminin receptor interaction [35]. Interestingly, an inverted
RGD domain is found in the rodent PrP protein at the C-terminus
(DGR aa 229–227) that is absent in other species.
Our data shows that pre-incubation of RADA with PrPsc brain
homogenate prior to inoculation is necessary for its anti-prion
activity. Moreover, we show that both PrPc and PrPsc bind
RADA and binding can be competitively inhibited with Congo
red. The planar dye Congo red has anti-prion activity and is
routinely used as an amyloid stain [36]. We also show that Congo
red binding competes with RADA for PrP binding and not by
binding RADA directly. This suggests that Congo red and RADA
share a common binding motif in PrPsc and implies a similar
mechanism by which they exert their anti-prion activity. Although
the mechanism by which Congo red binds amyloid and PrPsc has
not been elucidated, its anti-prion activity may be mediated
through stabilization of the PrPsc conformation that then impedes
the process required for PrPc conversion [37,38]. Interestingly,
Congo red has a strong self-assembling activity, a property that
other symmetric or planar dyes may share, in that they form
ribbon-like micellar species that may provide an adhesive
structure for binding beta-sheet peptide chains [39]. The
symmetrical self-assembled beta-sheet rich RADA-scaffold may
provide a complimentary surface for PrPsc binding and
consequently uncoupling the process necessary for PrPc to PrPsc
conversion.
Alternatively, the interaction of PrPsc with RADA may
competitively disrupt PrPsc binding to endogenous ECM
proteins. This could result in altered clearance of the
PrPsc+RADA complex or a distinct extracellular distribution. A
change in clearance of PrPsc mediated by RADA binding could
result in a reduced PrPsc titer retained in the brain that would
account for the delay in prion accumulation at 40 d and the
increased survival. Yet, this does not explain the progressive
increase in reactive gliosis from the time of inoculation, the
increased rate of PrPsc accumulation from 40- to 75 d with a
disconnect between the severity of clinical disease and total PrPsc.
However, this could be explained by an altered extracellular
Figure 5. Scrapie induced reactive gliosis and PrP aggregation is increased by RADA. Fig. 5A shows dual labeled immunofluorescent GFAP
(red) and PrP (green) hamster brain micrographs. Limited staining of GFAP and no detectable PrP was observed in PrPc+RADA treated brain after
115 d (top right panel). PrPsc treatment alone results in an increased detection of GFAP-positive astrocytes (red) and weak PrP protein (green, white
arrows) after 75 d (middle panel). Combined PrPsc+RADA treatment (right panel) results in abundant and strong detection of both GFAP-positive
astrocytes and large PrP deposits (green, arrows). V=ventricle. Bv=blood vessel. DAPI nuclei (blue). Bars=50 mm. Fig. 5B shows micrographs of
hamster brain sections labeled with GFAP (red) and IBA1 (green). Increased IBA1-positive immunoreactive microglia are detected in brain following
inoculation of PrPsc alone after 75 d (left panel; white arrows) and PrPsc+RADA after 115 d (middle panel; white arrows) as compared to PrPc+RADA
after 115 d (right panel; white arrows). IBA1 and GFAP immunoreactivity do not co-localize in dual labeled sections from PrPsc and PrPsc+RADA brain.
V=ventricle. DAPI nuclei (blue). Bars=50 mm.
doi:10.1371/journal.pone.0004440.g005
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secondary sites not normally involved in PrPc to PrPsc conversion
could act to sequester the PrPsc from it preferred neuronal site.
Here the PrPsc+RADA complex could be more susceptible to
protease degradation within the extracellular matrix or via
intracellular pathways. Indeed, the conversion of PrPc to PrPsc
can occur at multiple cellular sites [40,41]. If a predominant,
neuronal site is required for the neuropathological impact of
prion disease then accumulation at secondary sites, such as glia,
could alter the neuropathology. The progressive increase in
reactive gliosis observed in animals inoculated with PrPsc+RADA
suggests an active disease process but may reflect a more robust
neuro-protective response.
Future experiments will determine binding of prion from
different species and strains to RADA and the capability of
RADA to disrupt in vitro PrPc to PrPsc conversion. The
participation of an intrinsic rodent RGD-like motif in PrPc+
protein interaction might account for discrepancies in the efficacy
of prion conversion between species, strains, and anti-prion
compounds observed in assays based on the rodent PrP protein.
A further evaluation of PrP interaction with synthetic peptides
corresponding to RGD motifs may be useful in elucidating the
molecular mechanism by which certain compounds exert their
anti-prion activity and illuminate distinct biochemical properties
inherent in the structural variability of prions. We conclude that
RADA impedes the propagation of PrPsc from endogenous PrPc
Figure 6. PrP binds RADA-peptide and binding can be
inhibited with Congo red. Fig. 6A shows chemiluminescent
detection of PrP binding to RADA dilutions from Scrapie (PrPsc) and
normal (PrPc) brain homogenates. Fig. 6B shows quantification of PrP
binding to RADA (Control RADA/PrP) following pre-incubation with
dilutions of Congo Red. Fig. 6C compares the binding of PrP to RADA
based on the order of reagent addition. Quantification of PrP binding to
RADA: RADA followed by PrP (RADA+PrP), RADA followed by 1 mM
Congo red (CR) then PrP (RADA+CR+PrP), RADA followed by pre-
incubated PrP with 1 mM CR (RADA+CR/PrP), RADA pre-incubated with
1 mM CR followed by PrP (RADA/CR+PrP). RLU=relative light units.
doi:10.1371/journal.pone.0004440.g006
Table 2. RADA Promotes Survival.
PrPsc+RADA Mean 6SEM N
Group 1 111 2.5 13
Group 2 120 2.4 5
Group 3 117 1.9 6
Group 4 102 4.3 10
Groups 1–4 110 2.0 34
PrPsc alone 78 0.7 24
Survival data following intracerebral inoculation of hamsters with 1% Scrapie
brain homogenates (PrPsc) and 0.9% w/v RADA after 24 h. Four independent
groups consisting of PrPsc brain homogenate combined with RADA
(PrPsc+RADA) were evaluated for survival in days (Mean6SEM). The average
survival time in days of all PrPsc+RADA (Groups 1–4) inoculated hamsters is
compared to survival of those inoculated with equivalent doses of PrPsc alone.
N=number of animals.
doi:10.1371/journal.pone.0004440.t002
Table 3. Effect of RADA on Secondary Passage of Scrapie
Brain Homogenate.
Treatment MEAN 6SEM N
PrPsc 78 0.7 24
PrPsc/RADA 80 0 6
PrPsc/RADA+RADA 117 1.9 6
Survival data following intracerebral inoculation of hamsters with 263K Scrapie
brain homogenate following primary passage with RADA (PrPsc/RADA). Survival
(Mean6SEM) of hamsters inoculated with 1% Scrapie alone (PrPsc) is compared
to those inoculated with 1% PrPsc/RADA (homogenate derived from a 1%
PrPsc+0.9% w/v RADA infected brain) and 1% PrPsc/RADA combined a second
time with 0.9% w/v RADA. N=number of animals.
doi:10.1371/journal.pone.0004440.t003
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Materials and Methods
Animals
Female Syrian Golden hamsters (LVG) at 4 weeks of age were
housed in pairs on a 12 h light-dark cycle. Animals were provided
continual access to food and water. All protocols were approved
by the USDA animal care and use committee and experimental
procedures conducted in certified BL2 laboratory. PrPsc-infected
hamsters were sacrificed when clinical Scrapie symptoms
included; increased startle response, ataxia, and .5 s righting
reflex.
Reagents
Infectious 263K Scrapie was propagated by serial passage in
hamster brains for 72 days following intracerebral inoculation.
Infected or normal brains were frozen on dry ice and stored at
280 C until use. A 16-mer RADA peptide hydrogel was
purchased from BD Bioscience as Puramatrix (Product
#354250; Lot#425714) or synthesized to 95% purity (AnaSpec,
CA) for comparison. Congo red (Sigma-Aldrich, MO) was
solubalized in water at 1 mM. Ultra pure low melting temperature
agarose (AquaPor LM, National Diagnostics, GA) was dissolved in
water at 65 C and combined with brain homogenate to form
agarose plug controls.
Inoculation
Hamster brain homogenates (10%) were prepared by
homogenization in 320 mM sucrose and pre-cleared by centri-
fugation at 3000 RPM for 10 min at 4 C. Resulting supernatant
was processed for inoculation by 1:10 dilution in 320 mM
sucrose or PuraMatrix (1% w/v synthetic 16-mer RADA peptide
hydrogel) to yield a 1% brain homogenate (dose equivalent 10
22)
in 0.9% peptide hydrogel. Additionally, brain homogenate or
PuraMatrix was serially diluted in 320 mM sucrose and final
concentration of brain homogenate was achieved by 1:10
dilution in PuraMatrix. Samples were vortexed and incubated
at room temperature for 20 min prior to unilateral intracerebral
inoculation (40 ml) using a 27-guage needle attached to a 1 ml
syringe.
Western Blotting
Hamster brain homogenates were processed by homogenization
in a MES buffer (25 mM MES, 150 mM NaCl, 60 mM n-octyl-
glucoside and 1% Triton X-100, pH 6.5) at 4 C and protein
concentration quantified by BCA (Pierce, IL). Proteinase-K
treatment of 25 mg protein was performed at 60 C for 1 h at a
final concentration of 15 mg/ml followed by heat denaturation in
sample buffer. Equal concentration of protein (20 mg) were loaded
on 4–12% polyacrylamide gels and subjected to electrophoresis,
transferred to nitrocellulose and probed with anti-PrP mAb IPC1
at 1:10K (Sigma-Aldrich), rbt-a-GFAP 1:5K (Novus, CO), gt-a-
flotillin-1 at 1:1K (H-104; Santa Cruz, CA) or gt-a-contactin-1 at
1:200 (S-20; Santa Cruz). Corresponding secondary antibodies
were used; gt-a-m-HRP (Pierce, IL), gt-a-rbt-HRP (Pierce), or dnk-
a-gt-HRP (Jackson, PA) at 1:10K and blots resolved by ECL
(Supersignal Pico, Pierce) and imaged on Flurochem HD
documentation system (Alpha Innotech, CA).
ELISA assay
RADA-peptide hydrogel was diluted in 0.1 M sodium bicar-
bonate buffer (pH 8.6) and adsorbed to black 96-well Maxisorb
plates (Nunc, NY) at 4 C overnight. Plates were washed in TBS
with 0.1% Tween-20 (TBST), blocked with 10% non-fat dry milk
followed by incubation with dilutions of hamster brain homoge-
nate at 4 C for 18 h. Plates were washed, blocked a second time
and incubated with m-a-PrP (mAb IPC1; 10K) diluted in TBST
with 0.1% IgG-free BSA (Jackson) followed by gt-a-m-HRP
(1:10K) for 1 h. Plates were resolved by ECL (Supersignal Femto,
Pierce) and chemiluminescence detected using a Wallac Victor II
(PerkinElmer, MA).
Immunofluorescent microscopy
Hamster brains were fixed in 10% neutral buffered formalin
72 h at 4 C, sunk in 30% sucrose and 5 mm coronal cryosections
collected on glass slides. Sections were washed in 10 mM PBS
(pH 7.2) with 0.1% Triton-X100, blocked (Superblock, Pierce)
and incubated with m-a-PrP (IPC1, 1:1K) and rbt-a-GFAP (1:1K;
Novus) or ms-a-GFAP (1:1K; BD Biosciences) and rbt-a-IBA1
(1:200; Biocare Medical, CA) diluted in PBST-BSA for 2 h. Alexa
Fluor-488 gt-a-ms-IgG or Alexa Fluor-568 gt-a-rbt-IgG (Molecu-
lar Probes-Invitrogen, CA) diluted 1:1500 in PBST-BSA contain-
ing DAPI and incubated 1 h. Sections were imaged using a Leica
SP5 confocal microscope equipped with AOTF/AOBS and blue
Argon, Yellow DPSS (561 nm) and 405 nm lasers (Leica,
Germany).
Histochemistry
Hamster brains were fixed and 1 mm coronal sections cut using
a steel hamster brain matrix (EM sciences) and gross morphology
imaged using a Leica EZ4D stereo microscope. Thin cyrosections
were collected stained with CAT Hematoxylin (Biocare Medical),
dehydrated in graded-ETOH, cleared in Xylene, and coverslipped
using DPX (EM sciences). Sections were imaged using a Leica
DMI400B with an attached DFC320 R2 digital camera.
Statistics
Sigma Stat software was used for statistical analysis (Systat, CA).
Kruskal-Wallis one way analysis of variance on ranks was used
followed by pairwise comparison using Mann-Whitney U Rank
Sum Test.
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